The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Anticancer Res. 2012 Apr;32(4):1507-13.
Novel biomarkers which may serve as therapeutic targets are essential for lung cancer treatment. Here we investigated the prognostic significance of protein kinase Cη (PKCη), a cell cycle regulator involved in tumorigenesis and chemotherapy resistance, in patients diagnosed with non-small cell lung cancer (NSCLC).
Sixty-three chemotherapy-naïve patients were examined for PKCη by immunohistochemistry and divided into PKCη H-Score tertiles (low, intermediate and high). Time until event (relapse or mortality) within one year was determined using Cochran-Armitage test and Cox proportional hazards regression model.
The distribution of patients according to clinical stage 1-4 was: 27%, 5%, 26% and 42%, respectively. PKCη overexpression was associated with advanced stage (p=0.03) and the risk for an event (p=0.045). Patients of the lowest tertile were less likely to experience an event.
PKCη is a novel prognostic marker in NSCLC that may predict poor prognosis. The use of PKCη-specific inhibitors in NSCLC may prove valuable.
新型生物标志物可能作为治疗靶点，对于肺癌治疗至关重要。在此，我们研究了蛋白激酶 Cη（PKCη）在非小细胞肺癌（NSCLC）患者中的预后意义。PKCη是一种参与肿瘤发生和化疗耐药的细胞周期调节剂。
采用免疫组织化学法对 63 例未经化疗的患者进行 PKCη 检测，并根据 PKCη H 评分分为三分位（低、中、高）。采用 Cochran-Armitage 检验和 Cox 比例风险回归模型确定一年内发生事件（复发或死亡）的时间。
根据临床分期 1-4 分布的患者分别为：27%、5%、26%和 42%。PKCη 过表达与晚期（p=0.03）和事件风险（p=0.045）相关。最低三分位的患者发生事件的可能性较小。
PKCη 是 NSCLC 的一种新型预后标志物，可能预测不良预后。在 NSCLC 中使用 PKCη 特异性抑制剂可能具有价值。
